FYB.DE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:36):

Stats
今日成交量	4 802.00
平均成交量	8 148.00
市值	705.39M
EPS	€0 ( 2024-04-25 )
下一个收益日期	( €0 ) 2024-05-28
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	8.46
ATR14	€0.0820 (0.21%)

音量相关性

長: 0.06 (neutral)

短: 0.29 (neutral)

Signal:(57.427) Neutral

Formycon AG 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Formycon AG 相关性 - 货币/商品

-0.41
( neutral )

0.00
( neutral )

-0.38
( neutral )

0.40
( neutral )

0.32
( neutral )

Formycon AG 财务报表

Annual	2022
营收:	€42.50M
毛利润:	€12.07M (28.41 %)
EPS:	€2.62

FY	2022
营收:	€42.50M
毛利润:	€12.07M (28.41 %)
EPS:	€2.62

FY	2021
营收:	€36.97M
毛利润:	€1.01M (2.72 %)
EPS:	€-1.225

FY	2020
营收:	€34.23M
毛利润:	€8.76M (25.60 %)
EPS:	€-0.539

Financial Reports:

No articles found.

Formycon AG

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.